| Old Articles: <Older 7181-7190 Newer> |
|---|
 |
The Motley Fool
February 17, 2011
Brian Orelli |
Nice Deal, Now Let's See Some Data AVEO Pharmaceuticals struck a solid partnership with Astellas Pharma and its investors are rewarding the company today.   |
The Motley Fool
February 17, 2011
Brian Orelli |
What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate. |
Chemistry World
February 17, 2011
Sarah Houlton |
Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share. |
The Motley Fool
February 17, 2011
John Keeling |
An Inside Look at Biotech Investing A Fool community member talks about "baby biotech" stocks. |
Pharmaceutical Executive
February 1, 2011
Jill Wechsler |
The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome? |
Pharmaceutical Executive
February 1, 2011
Scott Moldenhauer |
Accelerated Evolution Adapting training techniques for pharmaceutical sales representatives is necessary to thrive in the fact-changing dynamic of a physician's office |
Pharmaceutical Executive
February 1, 2011
Sumit Nijhawan |
Worth a Pound of Cure In an era of information overload, continuous monitoring, solutions can prevent your pharma business from losing money and save a few lives along the way |
Pharmaceutical Executive
February 1, 2011
Jill Wechsler |
Challenges, Changes, Commitments The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency |
Pharmaceutical Executive
February 1, 2011
Stan Bernard |
Are You Trained to Compete and Win? With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace |
Pharmaceutical Executive
February 1, 2011
Stergiopoulos et al. |
Honing Reforms from Clinical Development Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities |
| <Older 7181-7190 Newer> Return to current articles. |
